Spicer DV, Pike MC. Future possibilities in the prevention of breast cancer: luteinizing hormone-releasing hormone agonists.
Breast Cancer Res 2000;
2:264-7. [PMID:
11250719 PMCID:
PMC138786 DOI:
10.1186/bcr67]
[Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2000] [Revised: 04/07/2000] [Accepted: 04/07/2000] [Indexed: 11/10/2022] Open
Abstract
The cyclic production of estrogen and progesterone by the premenopausal ovary accounts for the steep rise in breast cancer risk in premenopausal women. These hormones are breast cell mitogens. By reducing exposure to these ovarian hormones, agonists of luteinizing hormone-releasing hormone (LHRH) given to suppress ovarian function may prove useful in cancer prevention. To prevent deleterious effects of hypoestrogenemia, the addition of low-dose hormone replacement to the LHRH agonist appears necessary. Pilot data with such an approach indicates it is feasible and reduces mammographic densities.
Collapse